<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cognitive function after cancer and cancer treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cognitive function after cancer and cancer treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cognitive function after cancer and cancer treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary-Ellen Meadows, PhD, ABPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Ganz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21781038"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are over 18 million cancer survivors in the United States and over 40 million survivors worldwide [<a href="#rid1">1,2</a>]. This number is expected to grow due to improvements in cancer screening, increases in life expectancy following definitive cancer treatment, and the aging of the population. Despite these improvements, the late effects of treatment, in particular those related to chemotherapy, have become more concerning to patients. These late effects may include what patients have termed "chemobrain" or "chemofog," which can persist in some patients long after treatment has ended. It is also referred to as cancer-related cognitive impairment (CRCI) and chemotherapy-induced cognitive impairment (CICI) in the literature.</p><p>This topic will discuss cognitive function changes after cancer treatment, particularly as they relate to chemotherapy. Immunotherapy is now also a treatment modality for various cancers and can have adverse neurologic effects and fatigue, but there are no clinical studies as of yet that focus on cognitive functioning.</p><p>Cognitive function following craniospinal irradiation, as well as other issues in cancer survivorship, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation"</a> and  <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment"</a> and  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p class="headingAnchor" id="H171367"><span class="h1">IMPACT OF CANCER AND CANCER TREATMENT ON COGNITIVE FUNCTION</span></p><p class="headingAnchor" id="H811910843"><span class="h2">Neurobiologic basis</span><span class="headingEndMark"> — </span>The mechanisms by which cancer and cancer treatment impact cognitive function have not been elucidated. The following mechanisms have been proposed:</p><p class="headingAnchor" id="H684326086"><span class="h3">Effect of cancer therapy on trajectory of cognitive aging</span><span class="headingEndMark"> — </span>Some investigators have proposed that cancer treatment can either shift the trajectory of normal cognitive aging or accelerate the aging process [<a href="#rid3">3</a>]. Evidence that chemotherapy-related cognitive dysfunction is accompanied by structural changes in the central nervous system comes from cross-sectional magnetic resonance imaging (MRI) studies, most of which included breast cancer patients who were treated with chemotherapy months to years earlier; the control groups consisted of healthy individuals and breast cancer patients not treated with chemotherapy [<a href="#rid4">4-6</a>]. Patients who received chemotherapy were more likely than controls to manifest a long-term persisting diffuse decrease in gray matter and white matter volumes post-treatment, and these changes correlated with neurocognitive deficits.</p><p>Other research suggests that chemotherapy-related cognitive impairment may be related not only to altered neuronal integrity, but also to disruption of brain structural networks that process and integrate information across the brain. In a prospective study of 64 males with newly diagnosed testicular cancer who underwent orchiectomy, patients underwent baseline and six-month follow-up neurocognitive testing and MRI scanning, which provided data to construct theoretical brain structure networks [<a href="#rid7">7</a>]. Twenty-two males received <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and 42 had surveillance only. At six-month follow-up, compared with the surveillance group, males who had chemotherapy exhibited altered neuronal integrity and disruption of structural networks, as well as poorer cognitive performance. Patients with lower cognitive reserve appeared to be more vulnerable to these changes and to postchemotherapy cognitive decline.</p><p>It is likely that many mechanisms contribute to cognitive decline in cancer patients, including inflammation [<a href="#rid8">8</a>], direct neurotoxic effects of treatments, and damage to progenitor cells, among others [<a href="#rid9">9</a>]. In addition, it is also likely that the observed cognitive dysfunction in some patients reflects an interaction between multiple factors. As an example, in one review of the literature, the multifactorial nature of cognitive deficits in breast cancer patients was discussed [<a href="#rid10">10</a>]. Factors other than chemotherapy were deemed to be important beyond the impact from surgery or medical therapy. These included psychological states (eg, depression, anxiety), the presence of fatigue or menopause, and other comorbid conditions. These data highlighted the need for larger studies to better understand both the magnitude and mechanism of cognitive dysfunction in this population. Another potential interacting factor is lower pretreatment cognitive reserve, which may make patients more vulnerable to postchemotherapy cognitive decline [<a href="#rid7">7,11,12</a>].</p><p>It is important to note that the incidence of cognitive changes (due to chemotherapy predominantly) has been primarily conducted in patients treated with either hematological or breast malignancies. Earlier studies were retrospective and primarily within a year of undergoing treatment. Later studies have included prospective designs and longer follow-ups, with attempts to identify risk factors for developing chemotherapy-related cognitive changes as well as identify the underlying mechanisms.</p><p class="headingAnchor" id="H893702676"><span class="h3">Soil, seed, and pesticide model</span><span class="headingEndMark"> — </span>Others have conceptualized the interaction between cancer therapy and cognitive function as a "soil, seed, and pesticides" model. In this model [<a href="#rid13">13</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>The "soil" includes host-related factors (ie, what the individuals themselves provide in the development and treatment reactivity to cancer) such as genetics, immune reactivity, nutrition, and cognitive reserve.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "seed" refers to disease-related factors, including the cancer itself. It also includes tumor genetics, mutations, cytokines, and paraneoplastic disorders.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "pesticides" include treatments for the cancer. Although chemotherapy is used in the model, one could also extend it to include hormonal treatments and radiation therapy (RT). The mechanisms by which chemotherapy can impact cognition and brain function are not entirely understood. Many factors have been suggested, but none are mutually exclusive to the risk.</p><p></p><p class="headingAnchor" id="H171447"><span class="h2">Specific cognitive complaints</span><span class="headingEndMark"> — </span>Individuals who have been treated with chemotherapy may bring out issues related to cognition in a variety of ways. As examples, patient complaints taken from our practice include:</p><p class="bulletIndent1"><span class="glyph">●</span>"I have complete memory blocks"</p><p class="bulletIndent1"><span class="glyph">●</span>"My mind feels like jello…"</p><p class="bulletIndent1"><span class="glyph">●</span>"Some days I feel like a ditz"</p><p class="bulletIndent1"><span class="glyph">●</span>"I cannot multitask"</p><p class="bulletIndent1"><span class="glyph">●</span>"I lose my place and attention when trying to read"</p><p></p><p>Studies have reported a fairly consistent pattern regarding the experience of cognitive impairment, such that declines tend to be in the realms of memory, processing speed, and complex attention [<a href="#rid14">14</a>]. However, there has been a lack of consistency between studies assessing cognitive outcomes in cancer patients with respect to design and defining cognitive impairment. For example, one comprehensive review of the literature highlighted the discrepancies in the assessment of cognitive functioning, particularly among patients who have undergone chemotherapy [<a href="#rid14">14,15</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>A lack of a set standard to define cognitive impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Variability in which neuropsychological tests were utilized</p><p class="bulletIndent1"><span class="glyph">●</span>The range of statistical analyses employed across studies</p><p></p><p class="headingAnchor" id="H3575149749"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>While cognitive complaints may be subtle, they should be taken seriously by the patient's clinicians and medical providers. If the complaints persist months after the cessation of treatment and are impacting a patient's quality of life, including performance at work or home, a referral for neuropsychological evaluation is indicated in order to help with the differential with respect to the etiology of the cognitive issues and to help guide subsequent management.</p><p class="headingAnchor" id="H171492"><span class="h1">EVALUATING COGNITIVE FUNCTION</span><span class="headingEndMark"> — </span>The routine assessment of cognitive function (either before or after treatment) is not a standard practice, and evaluation is typically reserved for patients in whom cognitive impairment is negatively impacting quality of life or functional performance.</p><p>In general, assessments are mostly done as part of clinical research rather than as part of routine clinical practice. Most investigators include measures of neuropsychological functioning that characterize both cognitive domains and intellectual function at baseline, during treatment, and into follow-up [<a href="#rid16">16</a>]. As with most clinical research, control for bias is important, which is done through the use of prospective designs, incorporating control groups, and assessing for any cognitive decline compared with baseline using validated measures.</p><p>There are a number of methods to assess changes in cognitive function. One example is called the reliable change index (RCI). The RCI is the difference between two obtained scores for an individual divided by the standard error of the difference of the test utilized. It is a quantification of how much an individual score has changed and whether or not that change is reliable and clinically significant. The RCI has since been utilized by a variety of researchers. However, other investigators have made adjustments to the index [<a href="#rid17">17</a>].</p><p>Other methods to evaluate cognitive function in patients with cancer are available, such as the Mini Mental State Examination and the Montreal Cognitive Assessment. Further details on these assessments are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/109994.html" rel="external">"Patients with cancer: Clinical features and diagnosis of cognitive impairment and delirium", section on 'Cognitive impairment'</a> and  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Cognitive testing'</a>.)</p><p class="headingAnchor" id="H171427"><span class="h1">SPECIFIC CANCERS</span><span class="headingEndMark"> — </span>Cognitive dysfunction can be apparent in various cancers at the time of diagnosis and can range from as high as 90 percent in patients with a history of a brain tumor, 20 to 30 percent in adult patients with leukemia, to between 17 and 75 percent in patients following breast cancer [<a href="#rid18">18</a>]. The data associated with cognitive impairment and these tumors are discussed below.</p><p class="headingAnchor" id="H21781044"><span class="h2">Brain tumors</span><span class="headingEndMark"> — </span>There are few studies assessing the cognitive impact from the treatment of brain tumors, as it is difficult to parcel out the roles of the tumor itself and cranial irradiation effects with respect to any neuropsychological changes. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Neurocognitive effects'</a>.)</p><p>However, as the disease-free survival rate improves for these patients with the use of adjunctive chemotherapy and immunotherapy, the cognitive outcomes will likely become more important to assess. The impact of treatment response on cognition was shown in a phase II study in patients with recurrent glioblastoma treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, all of whom underwent neuropsychological testing at baseline and every six weeks posttreatment to assess cognition [<a href="#rid19">19</a>]. Those who showed an objective response and survival over six months showed cognitive impairments at baseline relative to the general population, but had improved scores at the 24-week time point. Those who had progressive disease showed a decline.</p><p class="headingAnchor" id="H21781050"><span class="h2">Hematologic malignancies</span><span class="headingEndMark"> — </span>Patients undergoing hematopoietic cell transplantation (HCT) may develop evidence of post-transplant cognitive decline, although in many cases, baseline cognitive dysfunction is present prior to HCT, possibly because they have previously received chemotherapy and/or radiation [<a href="#rid20">20-22</a>]. As an example, in one prospective study where a fairly liberal definition of cognitive decline was utilized (performance one standard deviation below the mean compared with normative data), 58 percent of patients were classified as having a baseline cognitive impairment prior to HCT [<a href="#rid20">20</a>].</p><p>In the setting of HCT, at least some data suggest that the intensity of the conditioning regimen influences the risk and timing of post-treatment cognitive impairment. In a longitudinal prospective study of 477 HCT recipients (236 autologous, 128 reduced-intensity allogeneic, 113 standard myeloablative allogeneic), those undergoing a full-intensity allogeneic HCT were at greatest risk of cognitive decline post-treatment, which was present at six months and persisted beyond three years [<a href="#rid12">12</a>]. Individuals undergoing reduced-intensity allogeneic HCT had evidence of delayed decline in cognitive functioning (primarily in visual memory and fine motor dexterity) that did not emerge until three years post-transplant, and cognitive functioning was largely spared in most patients after autologous HCT. At three years post-HCT, global cognitive impairment was present in 19 percent of autologous HCT recipients compared with 36 percent of allogeneic HCT recipients. Older age, male sex, lower education, income, and pretreatment cognitive reserve were all associated with post-HCT cognitive impairment.</p><p>Others have noted the following risk factors for post-treatment cognitive decline: cognitive reserve [<a href="#rid11">11</a>], educational level [<a href="#rid23">23</a>], disease and health status [<a href="#rid11">11,20,23</a>], use of total body irradiation (TBI) as a component of the conditioning regimen [<a href="#rid24">24</a>], chronic graft-versus-host disease, and fatigue [<a href="#rid23">23</a>]. Affective state has not necessarily emerged as a contributor to cognitive changes/impairments in group studies [<a href="#rid11">11,22</a>], though in individual patients, this can certainly be a factor.</p><p>Follow-up studies have shown that cognitive dysfunction may improve over time, but this has mainly been observed in individuals undergoing autologous HCT [<a href="#rid11">11,23,25-30</a>]. Studies that focused on allogenic HCT mostly show a decline in cognitive impairment over time with limited recovery [<a href="#rid24">24,31,32</a>]. Special care must be given to the psychological health of the transplant survivor and that of their spouse/partner, and involvement of mental health providers in the long-term care of the transplant survivor is essential. Recommendations for post-transplant evaluation and management are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Mental health'</a>.)</p><p class="headingAnchor" id="H21781056"><span class="h2">Breast cancer</span><span class="headingEndMark"> — </span>The cognitive late effects of chemotherapy have been studied extensively in patients treated for breast cancer for both chemotherapy and/or endocrine therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy</strong> – Patients with breast cancer who receive chemotherapy report higher impacts on cognitive function compared with those without cancer. As an example, in one case-control study involving 581 patients with breast cancer and 364 noncancer controls, 37 percent of patients reported a decline in cognitive function at six months follow-up after chemotherapy relative to pretreatment, versus 14 percent of controls over the same time period [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Studies have also identified specific clinical factors associated with a higher risk of cognitive decline in patients receiving chemotherapy, such as baseline fatigue, anxiety, depression, decreased cognitive reserve, and functional well-being [<a href="#rid33">33,34</a>]. In one study, older individuals with lower cognitive reserve exposed to chemotherapy had lower scores on tests of processing speed compared with controls and a group that did not have chemotherapy [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">In addition, other factors may predict for an increased predisposition to cognitive difficulties, such as changes in brain white matter microstructure [<a href="#rid35">35</a>] and specific molecular alterations [<a href="#rid36">36</a>]. As an example, one study which assessed both cognitive functioning and functional magnetic resonance imaging (MRI) documented slower processing speed and poorer reported executive functioning in breast cancer patients treated with chemotherapy compared with normal controls; those with an apolipoprotein E4 (APOE4) allele had significantly slower processing speed [<a href="#rid36">36</a>]. Other candidate genes (<em>COMT</em>, <em>MDR1</em>, <em>BDNF</em> and <em>GST</em>) did not influence cognitive performance. However, impaired functional connectivity was related to genetic polymorphisms among patients with breast cancer [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Cognitive impairment was also noted primarily in the domains of verbal and visuospatial abilities in one meta-analysis of 17 studies focusing on survivors treated with standard-dose chemotherapy for longer than six months [<a href="#rid37">37</a>]. Relevant modifiers (age, education, time since treatment, adjunct hormonal treatment) did not emerge as significant modifiers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine therapy</strong> – Beyond chemotherapy, data suggest that endocrine therapy (eg, selective estrogen receptor modulators and aromatase inhibitors) can negatively impact cognition [<a href="#rid38">38-40</a>]. However, the data have not been consistently reported and require further evaluation [<a href="#rid41">41,42</a>]. Imaging studies in this patient population have also been conducted and provide additional evidence of the potential impact of cytotoxic chemotherapy on the brain [<a href="#rid43">43-48</a>].</p><p></p><p class="bulletIndent1">In a randomized trial that included 552 patients with breast cancer assigned to adjuvant endocrine therapy with or without chemotherapy, all patients had a decline in self-reported cognitive function, but it was greater in those who additionally received chemotherapy at the three- and six-month follow-up assessments. However, these findings were not sustained at one year or beyond [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H942168680"><span class="h2">Ovarian cancer</span><span class="headingEndMark"> — </span>Evidence suggests that some patients may experience cognitive decline with chemotherapy treatments for ovarian cancer, though further study is needed to identify those patients at highest risk of impairment.</p><p>A study of 230 patients with newly diagnosed ovarian cancer utilized web-based cognitive screening assessments and self-reporting to examine processing speed, attention, and motor reaction times before, during, and after chemotherapy [<a href="#rid50">50</a>]. In this study, approximately 25 percent of patients experienced a decline in at least one of these areas during treatment, though the proportion fell to 18 percent six months following therapy. Typically, impairments were limited to just one area of function. Exploratory analyses suggested that cognitive decline with chemotherapy was associated with patient’s age and education level.</p><p>In another study of 18 patients with ovarian cancer, participants underwent structural and functional brain MRI and neuropsychological testing within four months of completing chemotherapy [<a href="#rid51">51</a>]. Compared with an age-, sex-, and education-matched control group, patients with ovarian cancer had apparent structural and functional alterations in the frontal and parietal brain regions, but there were no differences in neuropsychological measures between the two groups.</p><p class="headingAnchor" id="H3160405118"><span class="h2">Colon cancer</span><span class="headingEndMark"> — </span>Patients with colorectal cancer may experience cognitive decline relative to healthy controls irrespective of chemotherapy treatment and stage of disease.</p><p>A study of almost 300 patients with localized colorectal cancer and approximately 70 healthy controls assessed the effect of colorectal cancer on cognition using neuropsychological assessments at baseline (prior to chemotherapy, if given) and at six-month intervals [<a href="#rid52">52</a>]. Cognitive impairment was more frequent at baseline among the colorectal cancer patients than the healthy controls (43 versus 15 percent), and the difference persisted at the later assessments (6 and 12 months). Attention, memory, verbal learning, and processing speed were the most affected parameters. Among patients with colorectal cancer, there were no differences in cognitive assessments at any time point between those who received chemotherapy and those who did not. Additionally, 73 patients with metastatic cancer were compared with the patients with localized cancer and found to have similar levels of cognitive impairment. There were no associations between other modifiers (cognitive symptoms, fatigue, cytokine levels, and APOE4 allele) and cognitive impairment.</p><p class="headingAnchor" id="H3388054052"><span class="h2">Prostate cancer</span><span class="headingEndMark"> — </span>The effects of androgen deprivation therapy on cognitive function in prostate cancer survivors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14235.html" rel="external">"Overview of approach to prostate cancer survivors"</a>.)</p><p class="headingAnchor" id="H21781062"><span class="h2">Childhood cancers</span><span class="headingEndMark"> — </span>In general, individuals who were treated at a young age with higher doses of cranial irradiation may incur greater deficits [<a href="#rid53">53</a>]. Fortunately, due to changes in treatment protocols, the late cognitive effects in individuals treated for leukemia tend to be lower today than the original reports that dated back to the early 1980s. Multiple factors are associated with the reported incidence of cognitive decline, including the age of the child during treatment and type of treatment received. In addition, a preexisting history of a learning disability may make someone more vulnerable to developing late cognitive effects. These issues are particularly relevant given other data suggesting that childhood cancer survivors may have an increasing incidence of frailty, which may represent a more rapid aging process compared with their peers [<a href="#rid54">54</a>].</p><p>In adolescent and adult survivors of acute lymphoblastic leukemia (ALL), neuropsychological late effects may be apparent and seem to be dependent on the factors as above [<a href="#rid55">55</a>]. In studies assessing the late effects of chemotherapy (which is used as a central nervous system [CNS] prophylaxis), primarily intrathecal <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (IT-MTX), the results are variable. There are those studies that have found cognitive deficits or lower scores compared with normative data in these patients [<a href="#rid56">56,57</a>], particularly among those with a greater number of intrathecal injections [<a href="#rid58">58</a>], and others where no major deficits were observed [<a href="#rid59">59,60</a>]. One study has implicated folate depletion and homocysteine elevation as possible mediators of cognitive impairment in the ALL survivors [<a href="#rid61">61</a>]. Genetic polymorphisms in methionine synthase as well as in genes related to oxidative stress have also been associated with cognitive deficits in survivors of childhood ALL [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H21781074"><span class="h1">INTERVENTIONS</span><span class="headingEndMark"> — </span>Since the etiology of potential cognitive inefficiencies postchemotherapy is not well established, it is difficult to identify possible modifiers. In the meantime, interventions are focused on behavioral strategies and psychopharmacological approaches.</p><p>In cancer survivors who report persistent cognitive concerns after completing therapy, a combination of both behavioral and pharmacological treatments may result in improved cognitive functioning and perceived improvement in quality of life. Optimizing modifiable factors (ie, improved sleep, regular exercise, good nutrition, reducing stress) can lead to subjective improvements. Pharmacological interventions target specific symptoms and are patient-specific. However, a review of both pharmacological and non-pharmacologic interventions favored the latter in breast cancer patients [<a href="#rid64">64-67</a>]. In addition, psychoeducation of patients and partners has been shown to help improve affective state and develop coping strategies [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H172642"><span class="h2">Behavioral interventions</span><span class="headingEndMark"> — </span>Interventions aimed at developing compensatory strategies for cognitive issues prior to or during treatment for cancer have been studied in breast cancer populations [<a href="#rid64">64,66,70-72</a>] and in children treated for leukemia [<a href="#rid73">73-75</a>]. However, there are few randomized clinical trials assessing many of these interventions in cancer patients or survivors. Some cancer centers are now offering cognitive rehabilitation either in group or individual settings during and/or after treatment in order to help patients devise compensatory strategies proactively, which may not only help cope with cognitive impairment, but also improve distress.</p><p>Examples of cognitive and behavioral remediation include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relaxation </strong>– Relaxation and other mindfulness training is an emerging area of interest. Mindfulness-based relaxation techniques teach individuals to focus their attention and awareness in their everyday life as a way to manage their emotions and aspects of cognition. This is sometimes recommended given the usefulness of mindfulness treatment for attentional disorders [<a href="#rid76">76</a>]. While there are studies assessing its usefulness in improving the quality of life in cancer patients [<a href="#rid77">77</a>], there are no high quality data for whether these techniques improve cognition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical exercise programs </strong>– Physical exercise is a reasonable recommendation for patients with cancer who have cognitive concerns [<a href="#rid78">78</a>]. Although physical exercise is associated with improved cognition in a variety of studies (notably in children and older adults), randomized studies in patients who are treated for cancer are limited [<a href="#rid79">79</a>]. However, studies in breast cancer patients found that exercise interventions are associated with improved cognitive function [<a href="#rid80">80-84</a>]. Further details on role of physical activity in cancer survivors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occupational therapy </strong>– This is usually referred to as cognitive rehabilitation, which is typically done by some speech therapists, occupational therapists, and neuropsychologists. (See  <a class="medical medical_review" href="/z/d/html/2827.html" rel="external">"Physical rehabilitation for cancer survivors", section on 'Cognitive dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain-training programs </strong>– Brain-training computer-based programs (sometimes referred to as neurobics) use repetitive mental exercises to increase the brain's performance. These programs are commercially available but may be quite expensive.</p><p></p><p class="bulletIndent1">Several randomized trials suggest that these computer-based programs may improve and maintain cognitive function. In one randomized trial of mostly breast cancer patients treated with chemotherapy, computer-assisted cognitive rehabilitation in the presence of a neuropsychologist improved cognition and working memory compared with other interventions, such as home cognitive exercises or phone follow-up [<a href="#rid85">85</a>]. Similar results were seen in another randomized trial also conducted in breast cancer patients, in which memory and speed of processing computer training was compared with a wait list control [<a href="#rid64">64</a>]. While both showed some efficacy, speed of processing improvements resulted in transfer to other domains. In a more diverse group of cancer survivors treated with chemotherapy who reported persistent cognitive symptoms, a home/web-based cognitive rehabilitation program improved cognitive symptoms compared with standard care (no intervention) [<a href="#rid86">86</a>]. A separate randomized clinical trial in childhood survivors of acute lymphoblastic leukemia showed that computerized training benefits on cognition were maintained six months following training [<a href="#rid87">87</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electroencephalography (EEG) biofeedback </strong>– This technique, also termed neurofeedback, was assessed in a small group of breast cancer patients with self-reported cognitive impairments [<a href="#rid67">67</a>]. The treatment resulted in improvement in cognitive measures, fatigue, psychological scales, and sleep. These improvements were maintained at four weeks posttreatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group cognitive rehabilitation intervention </strong>– A randomized clinical study of 48 cancer survivors demonstrated that small-group intervention, including psychoeducation and cognitive exercises, led to improvements in patients’ self-reported cognitive complaints as well as memory on neurocognitive testing [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychoeducation </strong>– This entails educating patients regarding the possible cognitive late effects of treatment and is important as they transition from cancer patients to cancer survivors.</p><p></p><p class="headingAnchor" id="H172698"><span class="h2">Pharmacologic interventions</span><span class="headingEndMark"> — </span>Pharmacological treatment may be an appropriate intervention in order to improve cognition in patients previously treated for cancer. However, the data to support its use are limited, and no randomized clinical trials have been performed [<a href="#rid89">89-92</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS) stimulants </strong>– <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">Modafinil</a> and <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> are two CNS stimulants that have been evaluated in patients with cognitive declines after cancer treatment [<a href="#rid89">89,91,92</a>]. The limited data suggest they may improve cognitive function, although formal randomized trials specifically evaluating their impact on cognitive function have not been performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donepezil</strong> – <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">Donepezil</a>, a reversible acetylcholinesterase inhibitor, improved multiple areas of cognition (including attention/concentration, verbal and figural memory) at 24 weeks compared with baseline in one phase II trial of 35 patients with a brain tumor [<a href="#rid90">90</a>]. The use of this agent and other reversible acetylcholinesterase inhibitors for mild cognitive impairment in the general population are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Acetylcholinesterase inhibitors'</a>.)</p><p></p><p>Further management options for mild cognitive impairment in the general population are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment"</a>.)</p><p class="headingAnchor" id="H172826"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cancer, the late effects of treatment, in particular those related to chemotherapy, may include cognitive problems, which have been termed "chemobrain" or "chemofog." These issues can persist in some patients long after treatment has ended. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism by which cancer and cancer treatment impacts cognition has not been entirely elucidated. Some propose that cancer and cancer treatment may have an adverse effect on age-related cognitive changes. Others have conceptualized the interaction as a "soil, seed, and pesticides" model. In this model (see <a class="local">'Impact of cancer and cancer treatment on cognitive function'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "soil" includes host-related factors (ie, what the individuals themselves provide in the development and treatment reactivity to cancer) such as genetics, immune reactivity, nutrition, and cognitive reserve.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "seed" refers to disease-related factors, including the cancer itself. It also includes tumor genetics, mutations, cytokines, and paraneoplastic disorders.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "pesticides" include treatments for the cancer. Although chemotherapy is used in the model, one could also extend it to include hormonal treatments and radiation therapy (RT). The mechanisms by which chemotherapy can impact cognition and brain function are not entirely understood. Many factors have been suggested, but none are mutually exclusive to the risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The routine assessment of cognitive function (either before or after treatment) is not standard clinical practice, and evaluation is reserved for patients in whom cognitive impairment is negatively impacting quality of life or functional performance. (See <a class="local">'Evaluating cognitive function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive dysfunction can be apparent in various cancers at the time of diagnosis and can range from as high as 90 percent in patients with a brain tumor, 20 to 30 percent in adult patients with leukemia, to between 17 and 75 percent in patients with breast cancer. (See <a class="local">'Specific cancers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In cancer survivors who report persistent cognitive concerns after completing therapy, a combination of both behavioral and pharmacological treatments is likely to result in improved cognitive functioning and perceived improvement in quality of life. Optimizing modifiable factors (ie, improved sleep, regular exercise, good nutrition, reducing stress) can lead to subjective improvements. Pharmacological interventions target specific symptoms and are patient-specific. In addition, psychoeducation of patients and partners has been shown to help improve affective state and develop coping strategies. (See <a class="local">'Interventions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72:409.</a></li><li><a class="nounderline abstract_t">Ahles TA. Brain vulnerability to chemotherapy toxicities. Psychooncology 2012; 21:1141.</a></li><li><a class="nounderline abstract_t">Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 2012; 30:3675.</a></li><li><a class="nounderline abstract_t">Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014; 26:102.</a></li><li><a class="nounderline abstract_t">Simó M, Rifà-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 2013; 37:1311.</a></li><li><a class="nounderline abstract_t">Amidi A, Hosseini SMH, Leemans A, et al. Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Carroll JE, Nakamura ZM, Small BJ, et al. Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. J Clin Oncol 2023; 41:295.</a></li><li><a class="nounderline abstract_t">Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 65:123.</a></li><li><a class="nounderline abstract_t">Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest 2007; 25:373.</a></li><li class="breakAll">Meadows M.-E., Chang G, Jones JA, et al. Predictors of Neuropsychological Change in Patients with Chronic Myelogenous Leukemia and Myelodysplastic Syndrome (2013). Archives of Clinical Neuropsychology, in print.</li><li><a class="nounderline abstract_t">Sharafeldin N, Bosworth A, Patel SK, et al. Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. J Clin Oncol 2018; 36:463.</a></li><li class="breakAll">Foxhall LE, Rodriguez MA. Etiology of Cognitive Symptoms. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series), Springer Publishing, 2014. p.339.</li><li><a class="nounderline abstract_t">Vardy J, Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007; 63:183.</a></li><li><a class="nounderline abstract_t">Phillips NS, Khan RB, Li C, et al. Seizures' impact on cognition and quality of life in childhood cancer survivors. Cancer 2022; 128:180.</a></li><li class="breakAll">Ruff RM, Crouch JA. Neuropsychological test instruments in clinical trials. In: Handbook of clinical trials:  The neurobehavioral approach, Mohr E, Brouwers P (Eds), Lisse: Swets &amp; Zeitlinger, New York 1991.</li><li><a class="nounderline abstract_t">Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59:12.</a></li><li><a class="nounderline abstract_t">Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 2012; 30:3675.</a></li><li><a class="nounderline abstract_t">Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011; 13:660.</a></li><li><a class="nounderline abstract_t">Sostak P, Padovan CS, Yousry TA, et al. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003; 60:842.</a></li><li><a class="nounderline abstract_t">Harder H, Van Gool AR, Cornelissen JJ, et al. Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. Eur J Cancer 2005; 41:1007.</a></li><li><a class="nounderline abstract_t">Beglinger LJ, Duff K, Van Der Heiden S, et al. Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: a preliminary study. J Int Neuropsychol Soc 2007; 13:172.</a></li><li><a class="nounderline abstract_t">Harder H, Cornelissen JJ, Van Gool AR, et al. Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer 2002; 95:183.</a></li><li><a class="nounderline abstract_t">Jim HS, Small B, Hartman S, et al. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer 2012; 118:3407.</a></li><li><a class="nounderline abstract_t">Syrjala KL, Dikmen S, Langer SL, et al. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood 2004; 104:3386.</a></li><li><a class="nounderline abstract_t">Jacobs SR, Small BJ, Booth-Jones M, et al. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer 2007; 110:1560.</a></li><li><a class="nounderline abstract_t">Chang G, Meadows ME, Orav EJ, Antin JH. Mental status changes after hematopoietic stem cell transplantation. Cancer 2009; 115:4625.</a></li><li><a class="nounderline abstract_t">Friedman MA, Fernandez M, Wefel JS, et al. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 2009; 24:689.</a></li><li><a class="nounderline abstract_t">Harder H, Van Gool AR, Duivenvoorden HJ, et al. Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results. Eur J Cancer 2007; 43:2052.</a></li><li><a class="nounderline abstract_t">Ahles TA, Tope DM, Furstenberg C, et al. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996; 14:1457.</a></li><li><a class="nounderline abstract_t">Scherwath A, Schirmer L, Kruse M, et al. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 2013; 22:1509.</a></li><li><a class="nounderline abstract_t">Schulz-Kindermann F, Mehnert A, Scherwath A, et al. Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 39:789.</a></li><li><a class="nounderline abstract_t">Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol 2016; :JCO2016685856.</a></li><li><a class="nounderline abstract_t">Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28:4434.</a></li><li><a class="nounderline abstract_t">de Ruiter MB, Reneman L, Kieffer JM, et al. Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer. J Clin Oncol 2021; 39:3908.</a></li><li><a class="nounderline abstract_t">Harrison RA, Rao V, Kesler SR. The association of genetic polymorphisms with neuroconnectivity in breast cancer patients. Sci Rep 2021; 11:6169.</a></li><li><a class="nounderline abstract_t">Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012; 30:3578.</a></li><li><a class="nounderline abstract_t">Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26:955.</a></li><li><a class="nounderline abstract_t">Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007; 14:995.</a></li><li><a class="nounderline abstract_t">Mandelblatt JS, Small BJ, Luta G, et al. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol 2018; 36:JCO1800140.</a></li><li><a class="nounderline abstract_t">Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2011; 126:221.</a></li><li><a class="nounderline abstract_t">Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010; 28:1294.</a></li><li><a class="nounderline abstract_t">McDonald BC, Saykin AJ. Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations. Brain Imaging Behav 2013; 7:374.</a></li><li><a class="nounderline abstract_t">Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012; 30:274.</a></li><li><a class="nounderline abstract_t">McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010; 123:819.</a></li><li><a class="nounderline abstract_t">McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 2013; 30 Suppl:S117.</a></li><li><a class="nounderline abstract_t">Yoshikawa E, Matsuoka Y, Inagaki M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005; 92:81.</a></li><li><a class="nounderline abstract_t">Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun 2013; 30 Suppl:S109.</a></li><li><a class="nounderline abstract_t">Wagner LI, Gray RJ, Sparano JA, et al. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol 2020; 38:1875.</a></li><li><a class="nounderline abstract_t">Hess LM, Huang HQ, Hanlon AL, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 2015; 139:541.</a></li><li><a class="nounderline abstract_t">Correa DD, Root JC, Kryza-Lacombe M, et al. Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav 2017; 11:1652.</a></li><li><a class="nounderline abstract_t">Vardy JL, Dhillon HM, Pond GR, et al. Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol 2015; 33:4085.</a></li><li><a class="nounderline abstract_t">Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol 2013; 31:4407.</a></li><li><a class="nounderline abstract_t">Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol 2013; 31:4496.</a></li><li><a class="nounderline abstract_t">Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010; 102:881.</a></li><li><a class="nounderline abstract_t">Brown RT, Madan-Swain A, Walco GA, et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Pediatr Psychol 1998; 23:333.</a></li><li><a class="nounderline abstract_t">Mulhern RK, Wasserman AL, Fairclough D, Ochs J. Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol 1988; 6:315.</a></li><li><a class="nounderline abstract_t">Liu W, Cheung YT, Conklin HM, et al. Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J Cancer Surviv 2018; 12:398.</a></li><li><a class="nounderline abstract_t">Kingma A, Van Dommelen RI, Mooyaart EL, et al. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol 2002; 24:106.</a></li><li><a class="nounderline abstract_t">Rodgers J, Marckus R, Kearns P, Windebank K. Attentional ability among survivors of leukaemia treated without cranial irradiation. Arch Dis Child 2003; 88:147.</a></li><li><a class="nounderline abstract_t">Kamdar KY, Krull KR, El-Zein RA, et al. Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatr Blood Cancer 2011; 57:454.</a></li><li><a class="nounderline abstract_t">Cole PD, Finkelstein Y, Stevenson KE, et al. Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol 2015; 33:2205.</a></li><li><a class="nounderline abstract_t">Krull KR, Bhojwani D, Conklin HM, et al. Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013; 31:2182.</a></li><li><a class="nounderline abstract_t">Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2012; 135:799.</a></li><li><a class="nounderline abstract_t">Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex 2014; 54:33.</a></li><li><a class="nounderline abstract_t">Chan RJ, McCarthy AL, Devenish J, et al. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer 2015; 51:437.</a></li><li><a class="nounderline abstract_t">Alvarez J, Meyer FL, Granoff DL, Lundy A. The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 2013; 12:475.</a></li><li><a class="nounderline abstract_t">Cunningham AJ, Tocco EK. A randomized trial of group psychoeducational therapy for cancer patients. Patient Educ Couns 1989; 14:101.</a></li><li><a class="nounderline abstract_t">Taylor KL, Lamdan RM, Siegel JE, et al. Psychological adjustment among African American breast cancer patients: one-year follow-up results of a randomized psychoeducational group intervention. Health Psychol 2003; 22:316.</a></li><li><a class="nounderline abstract_t">Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007; 16:772.</a></li><li><a class="nounderline abstract_t">Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012; 21:176.</a></li><li><a class="nounderline abstract_t">Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav 2013; 7:543.</a></li><li><a class="nounderline abstract_t">Butler RW, Copeland DR, Fairclough DL, et al. A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy. J Consult Clin Psychol 2008; 76:367.</a></li><li><a class="nounderline abstract_t">Nazemi KJ, Butler RW. Neuropsychological rehabilitation for survivors of childhood and adolescent brain tumors: a view of the past and a vision for a promising future. J Pediatr Rehabil Med 2011; 4:37.</a></li><li><a class="nounderline abstract_t">Moore IM, Hockenberry MJ, Anhalt C, et al. Mathematics intervention for prevention of neurocognitive deficits in childhood leukemia. Pediatr Blood Cancer 2012; 59:278.</a></li><li class="breakAll">Zylowska L. The Mindfulness Prescription for Adult ADHD: An 8-Step Program for Strengthening Attention, Managing Emotions, and Achieving Your Goals., Trumpeter Books, Boston 2012.</li><li><a class="nounderline abstract_t">Lerman R, Jarski R, Rea H, et al. Improving symptoms and quality of life of female cancer survivors: a randomized controlled study. Ann Surg Oncol 2012; 19:373.</a></li><li><a class="nounderline abstract_t">Ligibel JA, Bohlke K, May AM, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022; 40:2491.</a></li><li><a class="nounderline abstract_t">Campbell KL, Zadravec K, Bland KA, et al. The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials. Phys Ther 2020; 100:523.</a></li><li><a class="nounderline abstract_t">Hartman SJ, Nelson SH, Myers E, et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory &amp; motion study. Cancer 2018; 124:192.</a></li><li><a class="nounderline abstract_t">Salerno EA, Culakova E, Kleckner AS, et al. Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study. J Clin Oncol 2021; 39:3283.</a></li><li><a class="nounderline abstract_t">Gokal K, Munir F, Ahmed S, et al. Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial. PLoS One 2018; 13:e0206874.</a></li><li><a class="nounderline abstract_t">Campbell KL, Kam JWY, Neil-Sztramko SE, et al. Effect of aerobic exercise on cancer-associated cognitive impairment: A proof-of-concept RCT. Psychooncology 2018; 27:53.</a></li><li><a class="nounderline abstract_t">Galiano-Castillo N, Arroyo-Morales M, Lozano-Lozano M, et al. Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial. Support Care Cancer 2017; 25:3551.</a></li><li><a class="nounderline abstract_t">Dos Santos M, Hardy-Léger I, Rigal O, et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial. Cancer 2020; 126:5328.</a></li><li><a class="nounderline abstract_t">Bray VJ, Dhillon HM, Bell ML, et al. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol 2017; 35:217.</a></li><li><a class="nounderline abstract_t">Conklin HM, Ashford JM, Clark KN, et al. Long-Term Efficacy of Computerized Cognitive Training Among Survivors of Childhood Cancer: A Single-Blind Randomized Controlled Trial. J Pediatr Psychol 2017; 42:220.</a></li><li><a class="nounderline abstract_t">Ercoli LM, Petersen L, Hunter AM, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 2015; 24:1360.</a></li><li><a class="nounderline abstract_t">Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009; 115:2605.</a></li><li><a class="nounderline abstract_t">Shaw EG, Rosdhal R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006; 24:1415.</a></li><li><a class="nounderline abstract_t">Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006; 23:35.</a></li><li><a class="nounderline abstract_t">Lundorff LE, Jønsson BH, Sjøgren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009; 23:731.</a></li></ol></div><div id="topicVersionRevision">Topic 16347 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://gco.iarc.fr/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on January 23, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35736631" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer treatment and survivorship statistics, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023994" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Brain vulnerability to chemotherapy toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008308" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716504" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence, mechanisms, and management of cancer-related cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23660455" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chemobrain: a systematic review of structural and functional neuroimaging studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617869" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36179271" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25483452" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17882646" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renaming "chemobrain".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17882646" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renaming "chemobrain".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29252122" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29252122" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17678745" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cognitive function after chemotherapy in adults with solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34468985" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Seizures' impact on cognition and quality of life in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34468985" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Seizures' impact on cognition and quality of life in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002127" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21558074" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629244" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective evaluation of neurological complications after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862749" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166316" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115332" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139882" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251983" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17685391" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Changes in cognitive functioning in the year after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19551887" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mental status changes after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767298" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719220" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622059" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Psychologic and neuropsychologic impact of autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22945857" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417661" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029304" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837957" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591652" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33731765" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The association of genetic polymorphisms with neuroconnectivity in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927526" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742545" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898668" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281396" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21046229" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142601" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996156" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184379" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20690040" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22613170" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15980995" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698992" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271671" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26456812" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27766586" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527785" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190124" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248696" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458059" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9782681" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422262" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484542" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990695" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538320" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Attentional ability among survivors of leukaemia treated without cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618410" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987702" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23650422" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918524" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Advanced cognitive training for breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632463" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neural correlates of chemotherapy-related cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623439" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23584550" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of EEG biofeedback on reducing postcancer cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized trial of group psychoeducational therapy for cancer patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12790260" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Psychological adjustment among African American breast cancer patients: one-year follow-up results of a randomized psychoeducational group intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17152119" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cognitive-behavioral management of chemotherapy-related cognitive change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271538" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955490" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540731" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757809" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Neuropsychological rehabilitation for survivors of childhood and adolescent brain tumors: a view of the past and a vision for a promising future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21938763" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mathematics intervention for prevention of neurocognitive deficits in childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21938763" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mathematics intervention for prevention of neurocognitive deficits in childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21913014" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Improving symptoms and quality of life of female cancer survivors: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576506" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065236" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926676" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory&amp;motion study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34406822" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485297" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28075038" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of aerobic exercise on cancer-associated cognitive impairment: A proof-of-concept RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28639097" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32996583" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056205" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27342301" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-Term Efficacy of Computerized Cognitive Training Among Survivors of Childhood Cancer: A Single-Blind Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25759235" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19309747" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The effect of modafinil on cognitive function in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549835" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16450661" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Use of methylphenidate in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648224" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
